-
Study of Skin Microbiome in Atopic Dermatitis Patients
Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema have higher concentrations of a certain bacteria (S. aureus), especially when their disease is active. The purpose of this study is (a) to see if reductions in another skin bacteria (C. acnes) plays a role in the overgrowth of S. aureus in eczema patients, and (b) to examine how the types of bacteria present in the skin of patients with eczema or psoriasis change with disease activity.
-
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules, scale, and crusts in palms and soles. This study evaluates how well risankizumab works compared to placebo (no medicine) to treat palmoplantar pustulosis. Study will assess change in Palmoplantar Pustulosis Area and Severity Index [PPPASI]. Risankizumab is an investigational drug being developed for the treatment of palmoplantar pustulosis. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who...
-
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi Prefilled Syringe for Injection) in Adult Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study will evaluate how safe risankizumab is for the treatment of plaque psoriasis and to assess change in disease symptoms. Risankizumab is an approved drug for the treatment of psoriasis. Around 3000 adult participants with a moderate to severe plaque psoriasis who had been prescribed risankizumab by their doctor will be enrolled in this study in multiple sites across Korea. The sample size for this...
-
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
This study to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous NSAID, DMARD and/or anti-TNF therapy.
-
Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis
Patients with inflammatory rheumatism very often have residual pain that is not easily relieved by conventional treatments. They can then use non-drug methods, such as physiotherapy, hypnosis or even cannabis. The aim of this study is to assess the percentage of patients who use cannabis to better relieve their pain or anxiety in chronic inflammatory rheumatism.
-
Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System
The objective of this study is to evaluate patient outcomes in regards to safety and effectiveness based on the clinical performance of the reference devices to further support the assessment of residual risk identified in the Clinical Evaluation Report for the Ortho Development Hip System.
-
Swiss Dermatology Network of Targeted Therapies (SDNTT)
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy. The registry will also evaluate safety clinical outcomes and health related quality of life.
-
SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE
This is a single-label open-arm mechanistic clinical study recruiting patients with psoriasis or psoriatic arthritis with elevated cardiovascular risk. Subjects enrolled in this study will receive statin treatment with rosuvastatin. The statin treatment in this study will be used as an intervention with widely known pleiotropic CV risk reduction effects, including anti-inflammatory reduction. Subjects will be studied before statin therapy and followed for 48 weeks on treatment. The primary outcome will be change in the coronary flow reserve (CFR) as measured by cardiac PET. Overall, this study will examine the impact of statin therapy on ...
-
Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients
The impact of tailored patient-provider communication to improve clinical trial recruitment, patient knowledge, and patient engagement will be studied. Tailored patient-provider communication refers to the individualization of patient-provider communication using patients' preferred methods of communication. This involves the utilization of social messaging such as e-mail or text and/or social media platforms. These communication methods purport to and meet individual patient needs whilst ensuring that information is received and in a format that is familiar to each patient. The primary outcomes of the proposed research is to...
-
Taltz in Combination With Enstilar for Psoriasis
Enstilar in combination with Taltz for plaque psoriasis.
231 - 240 of 276 Trials
- Psoriasis
-
- Psoriatic Arthritis
-
- Psoriatic Disease
- Stay Healthy
-
Community
- icon:
Navigation CenterLink text:Get free, personalized guidance and support for psoriasis and psoriatic arthritis. - icon:
Talk PsoriasisLink text:The world’s online support community for those impacted by psoriasis or psoriatic arthritis. - icon:
One to OneLink text:Are you newly diagnosed? Have questions? Connect with someone who’s been through it. - icon:
Our SpotLink text:A new website for parents, kids and teens with psoriasis and psoriatic arthritis!
Stay Informed
- icon:
Health WebcastsLink text:Hear world-class experts provide the latest information on psoriatic disease.
-
- Get Involved
-
- Events and Programs
- icon:
Team NPFLink text:Join a group of everyday people dealing with psoriatic disease by walking, running, cycling and DIY-ing for a cure. - icon:
More than Skin DeepLink text:Outsmart psoriasis and psoriatic arthritis from the inside out at this local event.
-
- Research
-
- NPF Funded Research
- icon:
Victor Henschel BiobankLink text:A collection of biological samples and clinical information used by qualified scientists to advance the field of psoriasis genetics.
-
- Medical Professionals
-
- Stay Up-to-date
- icon:
Journal of Psoriasis and Psoriatic ArthritisLink text:Dedicated to providing practical information and research to those working in psoriatic disease care. - icon:
Continuing EducationLink text:Please join us at one of our educational events designed for health care providers.
-
